- Agarose Bead Technologies (ABT) has expanded its Burgos, Spain facility, increasing its annual agarose resin production capacity to 100,000 liters.
- The expansion includes two new cleanroom facilities and additional storage to enhance supply chain reliability.
Agarose Bead Technologies (ABT) has completed a significant expansion of its facility in Burgos, Spain, adding 1000 sqm to boost its annual production capacity of agarose resins to 100,000 liters. This move positions the company among the largest agarose resin manufacturers in Europe, addressing rising global demand from the pharmaceutical and bioprocessing sectors.
The expansion includes the addition of two new cleanroom facilities, which will enable ABT to fulfill larger-scale orders and provide a more reliable supply chain for its customers. The increased storage space will help accommodate higher volumes of products, ensuring stability and consistency in deliveries.
The growing demand for high-quality agarose resins is driven by advancements in biopharmaceutical therapies, such as monoclonal antibodies, vaccines, and cell and gene therapies. These treatments require advanced purification processes, and ABT aims to support manufacturers by delivering critical materials for their production pipelines.
Carolina Egea, CEO of Agarose Bead Technologies, commented, “Our investment in expanding the Burgos facility is a direct response to the increasing global demand for high-quality agarose resins. This enhanced capacity will enable us to meet the evolving needs of the pharmaceutical industry, improve supply chain reliability, and reinforce our role as a trusted partner in the development of life-saving therapies.”
The facility expansion also aligns with ABT’s commitment to sustainability, incorporating energy-efficient systems and waste-reduction measures, ensuring continued compliance with industry standards for purity and performance in biopharmaceutical applications.
Overview of outsourcing trends 
